How BioPlus became a business two buyers wanted to own
Twenty-four consecutive quarters of growth. Roughly $750M to $2B. And positioning that held through two ownership changes and an integration.
The pattern that should not have happened
Twenty-four consecutive quarters of growth in specialty pharmacy isn’t normal.
In a market where contracts shift overnight, margins compress without warning, and competitors compete relentlessly on price, strong companies tend to spike, stall, or erode under operational complexity. Sustained performance at that level is rare enough that it changes the question people ask.
At first, the conversation about BioPlus was about growth. Then it shifted. Experienced operators and investors stopped asking how fast it was growing and started asking how it was built.
In healthcare, those aren’t the same question.
What BioPlus already had
By 2018, BioPlus was a respected independent specialty pharmacy with more than 30 years of operating history, real momentum, and a founder's conviction underneath it. Dr. Stephen Vogt had built the company on a belief that access to life-saving specialty medicines should be fast, easy, and compassionate.
The business was performing. But the market couldn’t see it.
Patients, providers, and pharma partners often did not know who BioPlus was. Competitors were consolidating. PBMs were tightening their grip. In a category drifting toward commoditization, a company that had earned a differentiated position was at risk of being read as interchangeable.
Recognizing what the moment required, Dr. Vogt brought in Mark Montgomery as President. Mark had scaled and sold Axium Healthcare Pharmacy to Kroger and understood something most founders learn too late.
Meaningful isn’t the same as buyable
A great company isn’t automatically a buyable one.
From the outside, nothing about BioPlus suggested a problem. But the pattern was familiar to anyone who has watched value leak quietly out of a strong business: growth that cannot be clearly explained, performance that depends on a small number of people, a promise the organization believes but has never made executable.
Buyers hesitate at that. They discount. Or they walk away.
Growth alone does not command a premium. Confidence does. Confidence that the business is understandable, that performance is repeatable, and that success doesn’t rest on a handful of people holding it together behind the scenes.
BioPlus had built something meaningful. Closing the gap between meaningful and buyable didn’t require changing the vision. It required building the system underneath it.
The work
Legacy DNA came into the business in 2017. In January 2018, Dr. Roxie Mooney took the CMO seat as an outside operator, joining the BioPlus leadership team and leading both the internal marketing organization and the embedded Legacy DNA team. She held that seat for seven years, across both transactions.
The work began with an audit of everything the market could see: branding, positioning, messaging, digital presence, customer experience, sales enablement, and reputation. What it surfaced wasn’t a marketing problem. It was a translation problem. BioPlus operated to a standard it had never made legible.
A market promise the organization could execute. BioPlus already delivered faster than the category. It had never turned that into something the market could hold it to. The Power of 2™, built on a 2 Hour Patient Acceptance Guarantee™, 2 Day Ready to Ship™, and 2 Click Refills™, all anchored to a vision to heal the world 2gether, became an operating standard measured weekly rather than a campaign run quarterly.
Once a company defines a standard like that, it has a choice: defend it or dilute it. BioPlus chose to defend it, repeatedly, including when defending it made growth harder.
Differentiation a buyer could verify. Positioning, brand architecture, and proof structured so that what the company claimed and what it delivered were the same thing under examination.
Growth that did not depend on individuals. Digital transformation of the customer-facing platform. Patient and provider co-creation programs. A direct-to-consumer channel that added millions in gross profit. Sales enablement built for reps working through disrupted channels.
This was one part of a larger effort. Dr. Vogt and Mark assembled a veteran leadership team, sharpened operational discipline, and aligned the company around a shared vision. The commercial work made that discipline visible to the market.
What held
Most transformation stories end at the exit. This one is more useful because it didn’t
BioPlus was acquired twice. In 2020 by CarepathRx, backed by Nautic Partners. In 2023 by Elevance Health, and integrated into CarelonRx.
Integration is where acquired value usually goes quiet. Large organizations standardize what they buy, reduce variance, and align new assets to existing systems. All of it rational. All of it capable of eroding the specific things that made the company worth acquiring.
What survives that process is the part that was built into the business rather than layered on top of it. The promise held because it had become an operating standard. The positioning held because it described something the company actually did. Performance held because it was embedded in systems and leadership depth rather than in a few people.
When Elevance evaluated BioPlus, it wasn’t simply acquiring a fast-growing company. It was acquiring a business it could trust to operate at scale inside a far more complex environment.
"Dr. Roxie sees what most leaders miss. Not just how to grow a business, but how to build one that holds its value when it's tested. Her work with BioPlus is a clear example. She didn't just support one successful exit, she helped shape two."
Mark Montgomery, Former CEO, BioPlus Specialty Pharmacy, in the foreword to Winning in Healthcare
The outcome
Twenty-four consecutive quarters of growth
Revenue from roughly $750M to $2B
Gross profit up 202% in three years
Dispenses from 78K to 325K, a 22.5% CAGR over seven years
Ranked #1 in oncology specialty pharmacy care by both patients and prescribers
Acquired by CarepathRx in 2020, and by Elevance Health in 2023
"We had something good. Legacy DNA made it better. And then some."
Dr. Stephen Vogt, PharmD, Founder and CEO, BioPlus Specialty Pharmacy
What this means for your company
What made BioPlus valuable wasn’t size. It was clarity. A promise the organization could execute. Growth that could be explained. Performance that didn’t depend on the people who built it.
Premium outcomes are rarely created at the moment of exit. They’re built long before it, and the work that makes a business legible to a buyer is the same work that makes growth predictable now.
That work is what the Enterprise Value Creation System™ sequences. See the framework here.
Start with a Strategic Fit Call
Forty-five minutes. No pitch. You’ll know quickly whether this is a fit.